[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"menorrhagia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:menorrhagia":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,55,87,112,162,184,207],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":35,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100644230","phase-4-cyclobenzaprine-for-postoperative-pain-in-minimally-invasive-hysterectomy-100644230",false,"NCT07664956","Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy","Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age \\>18yo\n* Female\n* English speaking\n* Undergoing (robotic assisted or classic) total laparoscopic hysterectomy ± unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy\n* If other procedures such as lysis of adhesions, excision of endometriosis, or ureterolysis are indicated based on intraoperative evaluation, those patients may still be included\n* Surgery took place at ChristianaCare Hospitals\n* No allergies or contraindications to standard of care post operative pain medications (acetaminophen, NSAIDs, narcotics) or cyclobenzaprine\n\nExclusion Criteria:\n\n* Age \\\u003C18yo\n* Male\n* Pregnant, breastfeeding\n* Non-English speaking\n* Primary procedures other than laparoscopic hysterectomy\n* Laparoscopic myomectomy\n* Laparoscopic resection of endometriosis\n* Laparoscopic unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy ± unilateral or bilateral cystectomy without hysterectomy\n* Hysteroscopic procedures\n* Bartholin gland marsupialization\n* Operations that are scheduled as or converted to the open approach\n* Procedures with planned or unplanned bladder or bowel surgery\n* Allergies or contraindications to standard post operative pain control medications (acetaminophen, NSAIDs, narcotics), such as kidney or liver damage\u002Ffailure, bariatric surgery, history of gastric ulcer, etc.\n* Chronic pain issues, whether self-diagnosed or by a physician, currently undergoing management\n* Currently undergoing medication assisted treatment for opioid use disorder\n* Currently using opioids consistently\n* Allergies or contraindications to cyclobenzaprine:\n* Absolute: use of MAO inhibitors within 14 days, recent heart attack, congestive heart failure, heart block or other conduction abnormalities, cardiac arrhythmias, hyperthyroidism, history of serotonin syndrome\n* Allergies or contraindications to inactive ingredients in Flexeril, such as lactose\n* Patient's receiving gabapentin at baseline or postoperatively, due to potential sedating effects, or other sedating drugs such as scheduled benzodiazepines and barbiturates","FEMALE","18 Years",{"count":19,"type":20},36,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Typical postoperative pain control after minimally invasive hysterectomy includes ibuprofen, acetaminophen, and a short course of narcotics. The purpose of this study is to see if adding cyclobenzaprine to this regime improves pain control and lessens narcotic use.",[26,27,28,29,30,31,32,33,34],"Minimally Invasive Surgical Procedures","Abnormal Uterine Bleeding, Unspecified","Adenomyosis of Uterus","Fibroid Uterus","Chronic Pelvic Pain","Endometriosis","Menorrhagia","Endometritis","Adnexal Diseases",[36,37,38,39,40,41],"cyclobenzaprine","flexeril","hysterectomy","minimally invasive hysterectomy","pain control","multimodal pain control","NOT_YET_RECRUITING","2026-06-18",{"date":45,"type":46},"2026-06-24","ACTUAL",{"date":48,"type":20},"2026-07-01",{"date":50,"type":20},"2026-12-01",{"name":52,"class":53},"Christiana Care Health Services","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":16,"minAge":63,"maxAge":4,"enrollmentInfo":64,"targetDuration":66,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100510147","a-registry-to-gather-real-world-use-data-on-the-cerene-cryotherapy-device-100510147","NCT05922657","A Registry to Gather Real World Use Data on the Cerene® Cryotherapy Device","A Prospective, Observational, Multi-center Study to Gather Real World Use Data on the Effectiveness, Safety, and Site-of-service of the Cerene Device","Progress","Inclusion Criteria:\n\n* Scheduled for a Cerene treatment\n* 25 years of age and older\n* Provided informed consent to participate in the registry\n* English speaking\n* Agrees to complete a survey at specified time points from baseline to 12 Months\n\nExclusion Criteria:\n\n* Physician discretion\n* Vulnerable populations","25 Years",{"count":65,"type":20},300,"1 Year","OBSERVATIONAL","Channel Medsystems, Inc., the manufacturer of the Cerene® Cryotherapy Device (Cerene), is initiating a prospective, observational registry, the Progress registry, to gather data during real world utilization of the Cerene® Cryotherapy Device (Cerene). The primary objective of this registry is to bridge the gap between clinical results and outcomes achieved and reported during the pivotal study of Cerene and those obtained during its real-world use.",[70,71,32],"Heavy Menstrual Bleeding","Abnormal Uterine Bleeding",[73,74,75],"Cerene","Registry","Cryoablation","RECRUITING",{"date":78,"type":46},"2026-06-22",{"date":80,"type":46},"2023-06-09",{"date":82,"type":20},"2027-12-31",{"name":84,"class":85},"Channel Medsystems","INDUSTRY",2,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":94,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":54},"100622013","phase-3-to-evaluate-the-efficacy-and-safety-of-klh-2109-in-patients-with-uterine-fibroids-and-menorrhagia-100622013","NCT07378098","to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia","A Multi-center, Randomized, Double-blind, Active-controlled, Parallel, Phase 3 Study to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia","Inclusion Criteria:\n\n* Individuals diagnosed with uterine fibroids\n\nExclusion Criteria:\n\n* Metrorrhagia or anovulatory bleeding\n* Patients with a history of total hysterectomy or bilateral oophorectomy","19 Years",{"count":96,"type":20},254,[98],"PHASE3","The goal of this clinical trial was to determine whether the investigational drug KLH-2109 is effective for treating excessive menstrual bleeding in patients with uterine fibroids. Uterine fibroids are benign tumors that grown in the uterus.\n\nThe primary objectives of this trial were to answer the following questions:\n\n* Does KLH-2109 lower the amount of menstrual bleeding?\n* Does KLH-2109 reduce menstrual bleeding?\n* Is KLH-2109 safe for participants to use?\n\nInvestigators will compare KLH-2109 with a standard of care treatment (control) to determine which treatment is more effective.\n\nParticipants will be required to follow:\n\n* Take either KLH-2109 or the common treatment as a pill\n* Visit the clinic regularly for health checkups and safety tests\n* Keep track of their bleeding and any health changes during the study",[32,101],"Uterine Fibroids",[101,32],"2026-04-27",{"date":105,"type":46},"2026-05-01",{"date":107,"type":46},"2026-02-03",{"date":109,"type":20},"2028-09-03",{"name":111,"class":85},"JW Pharmaceutical",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":120,"sex":121,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":161},"100383878","pharmacokinetics-pharmacodynamics-and-safety-profile-of-understudied-drugs-administered-to-children-per-standard-of-care-pops-100383878","NCT04278404","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs","POPS or POP02","Inclusion Criteria:\n\n1. Participant is \\\u003C 21 years of age\n2. Parent\u002F Legal Guardian\u002F Adult Participant can understand the consent process and is willing to provide informed consent\u002FHIPAA:\n3. (a) Participant is receiving one or more of the study drugs of interest at the time of enrollment or (b) Participant is NOT receiving one or more of the study drugs of interest but is SARS-COV-2 positive within 60 days prior to enrollment\n\nExclusion Criteria:\n\n1. Participant has a known pregnancy\n\n   Below exclusion criteria apply only to:\n\n   Participants receiving one or more of the study drugs of interest at the time of enrollment, DOI administration or PK sampling: (Refer to DOI specific appendices for details on enrollment cohort specifications and additional eligibility criteria)\n2. Has had intermittent dialysis within previous 24 hours\n3. Has had a kidney transplant within previous 30 days\n4. Has had a liver transplant within previous 1 year\n5. Has had a stem cell transplant within previous 1 year\n6. Has had therapeutic hypothermia within previous 24 hours\n7. Has had plasmapheresis within the previous 24 hours\n8. Has a Ventricular Assist Device\n9. Has any condition which would make the participant, in the opinion of the investigator, unsuitable for the study",true,"ALL","0 Years","20 Years",{"count":125,"type":20},5000,"The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.",[128,129,130,131,132,133,134,135,136,137,138,32,139,140,141,142,143,144,145,146,147,148,149,150,151],"Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hypertension","Pain","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Heart Failure","Hemophilia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Coagulation Disorder","Down Syndrome","2026-03-31",{"date":154,"type":46},"2026-04-06",{"date":156,"type":46},"2020-03-05",{"date":158,"type":20},"2027-07",{"name":160,"class":53},"Duke University",51,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":120,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":170,"targetDuration":172,"studyType":67,"phases":4,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":54},"100607415","prevalence-and-impact-on-quality-of-life-academic-performance-and-blood-indices-of-heavy-menstrual-bleeding-among-female-students-in-assiut-university-egypt-100607415","NCT07188259","Prevalence and Impact on Quality of Life, Academic Performance, and Blood Indices of Heavy Menstrual Bleeding Among Female Students in Assiut University, Egypt","Prevalence and Impact of Heavy Menstrual Bleeding Among Female Students in Assiut University, Egypt","menorrhagia","Inclusion Criteria:\n\n1- Female students of Assiut University.\n\nExclusion Criteria:\n\n1. Females known to have chronic anemia or hemolytic anemia by history\n2. Females on anticoagulation treatment.\n3. Females known to have coagulopathy.\n4. Females with any chronic condition (diabetes mellitus, liver diseases, etc.) in the previous 12 months were excluded from participation in this study.\n5. Females with a history of prior pregnancy (gravidity ≥1), regardless of outcome (live birth, miscarriage, abortion, or ectopic).",{"count":171,"type":20},340,"2 Months","The cause of menstrual disorders is unknown because many female students, embarrassed or unsure of what is \"normal,\" never seek care. In young females, abnormal uterine bleeding is usually functional-reflecting immaturity or dysregulation of the hypothalamic-pituitary-ovarian axis, anovulatory cycles, or inherited bleeding disorders-while serious structural pathology is rare. Nevertheless, early bleeding can be the first sign of conditions such as polycystic-ovary syndrome, endometriosis, or von Willebrand disease. It is the primary source of iron-deficiency anemia in females before marriage, leading to chronic fatigue, diminished academic performance, and lower exam results.\n\nA sectional study will be performed using a semi-structured questionnaire to assess the presence of HMB using the SAMANTA scale after its Arabic validation, and also evaluate the effect of HMB on quality of life using the validated heavy menstrual bleeding scale and assess impact on academic performance finally both females with positive HMB or not will asked to do Complete blood count (CBC), serum ferritin and coagulation profile.",[32],"2025-09-20",{"date":177,"type":46},"2025-09-23",{"date":179,"type":20},"2025-11",{"date":181,"type":20},"2027-06",{"name":183,"class":53},"Assiut University",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":21,"phases":194,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":4},"100574731","efficacy-of-calcium-dobesilate-versus-tranexamic-acid-for-treating-heavy-menstrual-bleeding-100574731","NCT06763094","Efficacy of Calcium Dobesilate Versus Tranexamic Acid for Treating Heavy Menstrual Bleeding","Efficacy of Calcium Dobesilate As an Alternative Method for Treatment of Menorrhagia, Comparison to Tranexamic Acid","Inclusion Criteria:\n\n1. Patients age 18 to 39 years\n2. Patients with menorrhagia\n3. Incidence of breakthrough bleeding while on treatment\n4. Patient with heaviness of the bleeding\n\nExclusion Criteria:\n\n1. Patients with hemoglobin less than 7gm\u002Fdl\n2. Patient with pelvic pathologies like uterine fibroids, suspected adenomyosis, malignancies of uterus\u002Fcervix\u002Fovary\u002Fvagina\u002Fendometrial hyperplasia with atypia.\n3. Patient with medical diseases like liver dysfunction, heart disease, migraine, stroke, renal disease, hypo\u002Fhyperthyroidism, platelet disorders or coagulopathy.\n4. Patient with previous history of thrombosis; pregnancy, abortion, use of IUCDs or oral contraceptives; lactating women in first 6 months of post-natal period and hypersensitivity to the drug","39 Years",{"count":193,"type":20},100,[195],"NA","The goal of this clinical trial is to determine if calcium dobesilate is an effective alternative to tranexamic acid for treating menorrhagia in women aged 18 to 39 years. The main questions it aims to answer are:\n\nDoes calcium dobesilate reduce menstrual blood loss and improve hemoglobin levels as effectively as tranexamic acid? What side effects and acceptability differences exist between calcium dobesilate and tranexamic acid? Researchers will compare calcium dobesilate to tranexamic acid to see if calcium dobesilate is as effective in reducing heavy menstrual bleeding and improving patient outcomes.\n\nParticipants will:\n\nTake calcium dobesilate or tranexamic acid during their menstrual cycle for three consecutive cycles.\n\nRecord menstrual blood loss using the Pictorial Blood Loss Assessment Chart (PBAC).\n\nAttend follow-up visits after each menstrual cycle to monitor hemoglobin levels, menstrual symptoms, and any side effects.",[32,71],"2025-01-01",{"date":200,"type":46},"2025-01-08",{"date":202,"type":20},"2025-01-05",{"date":204,"type":20},"2025-12",{"name":206,"class":53},"University of Health Sciences Lahore",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":32,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":121,"minAge":213,"maxAge":17,"enrollmentInfo":214,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":216,"conditions":217,"keywords":218,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":4},"100566844","pattern-of-menorrhagic-female-attending-the-hematology-unit-in-assuit-university-children-hospital-100566844","NCT06660459","Pattern of Menorrhagic Female Attending the Hematology Unit in Assuit University Children Hospital","Inclusion Criteria:\n\n\\- 1. Age of female patients range from (9 -18) years old.\n\n2\\. Girls with heavy menstrual bleeding\n\nExclusion Criteria:\n\n* 1\\. Patients on medication affecting coagulation profile. 2. Patients with pre-existing illness as chronic lung, liver, renal disease or malignancy.","8 Years",{"count":215,"type":20},50,"To Evaluate Causes of Menorrhagia in Adolescent FemalesSpecially Hematological causes to help in management of abnormal uterine bleeding.",[32],[32],"2024-10-24",{"date":221,"type":46},"2024-10-28",{"date":223,"type":20},"2024-10-20",{"date":225,"type":20},"2025-11-20",{"name":183,"class":53}]